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Abstract
Introduction: Physiologically relevant pre-clinical ex vivo models recapitulating CNS tumor micro-environmental complexity
will aid development of biologically-targeted agents. We present comprehensive characterization of tumor aggregates
generated using the 3D Rotary Cell Culture System (RCCS).
Methods: CNS cancer cell lines were grown in conventional 2D cultures and the RCCS and comparison with a cohort of 53
pediatric high grade gliomas conducted by genome wide gene expression and microRNA arrays, coupled with
immunohistochemistry, ex vivo magnetic resonance spectroscopy and drug sensitivity evaluation using the histone
deacetylase inhibitor, Vorinostat.
Results: Macroscopic RCCS aggregates recapitulated the heterogeneous morphology of brain tumors with a distinct
proliferating rim, necrotic core and oxygen tension gradient. Gene expression and microRNA analyses revealed significant
differences with 3D expression intermediate to 2D cultures and primary brain tumors. Metabolic profiling revealed
differential profiles, with an increase in tumor specific metabolites in 3D. To evaluate the potential of the RCCS as a drug
testing tool, we determined the efficacy of Vorinostat against aggregates of U87 and KNS42 glioblastoma cells. Both lines
demonstrated markedly reduced sensitivity when assaying in 3D culture conditions compared to classical 2D drug screen
approaches.
Conclusions: Our comprehensive characterization demonstrates that 3D RCCS culture of high grade brain tumor cells has
profound effects on the genetic, epigenetic and metabolic profiles of cultured cells, with these cells residing as an
intermediate phenotype between that of 2D cultures and primary tumors. There is a discrepancy between 2D culture and
tumor molecular profiles, and RCCS partially re-capitulates tissue specific features, allowing drug testing in a more relevant
ex vivo system.
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Introduction
Brain tumors are the leading cause of cancer related death in
children and adults up to the age of 40, accounting for 10,000 lost
years of expected life annually in the UK. High grade invasive
brain malignancies recur despite multimodal therapy; hence there
is an urgent need to develop new treatment strategies to improve
outcome. The imbalance in compound efficacies between in vitro
and in vivo experiments has considerably hampered the discovery
and development of a more effective and diverse armament of
chemotherapeutic agents [1]. As a result, only ,5% of cancer
drug candidates that enter clinical trials will ever receive approval
from the U.S. Food and Drug Administration, representing a huge
financial and clinical burden [2,3]. The lack of pediatric brain
tumor models in particular, has meant that chemotherapy drugs
that are currently prescribed had been initially developed for the
treatment of adult central nervous system (CNS) and other solid
tumors. This ignores accumulating evidence that adult and
pediatric brain tumors, although histologically similar are molec-
ularly distinct [4] and hence harbor distinct oncogenic mutations
that may provide novel therapeutic targets. As next-generation
therapy moves towards specific biological and pathway-related
targets, evaluation of drug efficacy and improved treatment will be
achieved not only via novel drug discovery, but also through
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improved pre-clinical ex vivo models that better recapitulate micro-
environmental complexity [5]. There is growing appreciation of
the intratumoral heterogeneity of high grade brain tumors with the
existence of differing cell populations within the same tumor that
each display different molecular changes [6]. Current pre-clinical
drug testing models do not replicate these key features.
Two-dimensional (2D) monolayer cell cultures represent a highly
reductionist model of cancers due to the loss of physiological
extracellular matrix (ECM) on artificial plastic surfaces. Conse-
quently, cells under these conditions adapt by altering gene
expression patterns and signaling networks, lose relevant proper-
ties such as differentiation, polarization and cell-cell communica-
tion, and artificially promote hyper-proliferation [1,7]. The ease of
drug uptake into a homogenous cell population on adherent 2D
surfaces, also likely results in an overestimation of efficacy
determined from in vitro cytotoxic screens, leading to ineffective-
ness of candidate agents in vivo [8]. Moreover, 2D cultures lack
complex 3D tissue structure and therefore hamper efforts to test
the effectiveness of certain candidate compounds such as anti-
angiogenic/vasculogenic agents prior to in vivo strategies [8].
Indeed 2D cytotoxic screens almost exclusively identify anti-
proliferative candidate agents [9,10].
There is a growing recognition conceptually that three-
dimensional (3D) culture technologies may more accurately reflect
tumor pathophysiology and recapitulate the in vivo tumor micro-
environment in vitro. As pharmacological responses in xenograft
studies do not consistently correlate with the clinical response, it is
imperative that better human-specific predictive models are
developed at a pre-clinical stage. Consequently, these models
should better inform xenograft studies and early clinical trials in
terms of predicting the pharmacological response to chemother-
apeutic compounds [11,12,13] thereby additionally reducing the
requirement of substantial numbers of animals for anti-cancer
drug testing.
Multicellular spheroids are small in vitro aggregates ranging from
100–1000 mm in diameter and commonly cultured in suspension
using spinner flasks, collagen gels and liquid-overlays [14]. The
size of the cultured spheroid is limited to less than 1 mm by shear
forces in the culture system and lack of internal cohesion/ECM
within the spheroid. The geometry of the spheroid contributes to
the formation of heterogeneous cell populations: the outer layer
proliferates comparably to monolayer cultures; the inner layer of
cells can become quiescent; and the core of spheroids can develop
necrosis [15]. The proliferation of tumor cells grown in 3D
spheroids is typically slower than that of monolayer cultures,
exhibits different metabolic profiles and typically displays reduced
sensitivity to chemotherapy and radiotherapy [7,16,17,18,19,20].
For example, cytosine arabinoside (Ara-C) and Taxol which
inhibit proliferation of glioblastoma cell lines in 2D cultures, but
have failed clinical trials, show markedly reduced sensitivity in 3D
cultures; an Ara-C dose 10 times higher than the effective dose in
2D cultures was necessary to reduce tumor cell proliferation
[21,22,23]. A more recent 3D spheroid culture system from the
Eccles and colleagues has provided automated, quantitative
imaging capability that is potentially compatible with high-
throughput preclinical targeting studies and may reduce the
requirement of animal studies. Moreover functional assays of
tumor migration and invasion are permitted in this system, thus
facilitating drug screening that covers a broad range of compounds
[24]. Consistently, gene expression signatures of primary cell
cultures are maintained in spheroid cultures such as glioblastoma
[25,26].
Biological gels such as Matrigel have also been used as
a substrate for spheroid growth. Matrigel is a basement membrane
extract derived from the Engelbreth-Holm-Swarm mouse sarcoma
that contains a diverse array of components, including collagen
type IV, laminin and other ECM molecules, in addition to soluble
signals such as cytokines and growth factors [27]. LaBarbera and
colleagues demonstrated that tumor-related phenomena such as
epithelial-mesenchymal transition in metastatic breast tumors can
be recapitulated in 3D matrigel-based spheroid culture, a system
additionally used as a high-throughput screening tool for small
molecule inhibitors for breast carcinoma [28]. However, as
Matrigel is a largely undefined and variable mixture of proteins,
it has not been used widely for drug screening purposes. Porous
collagen/hyaluronic scaffolds provide a more physiologically
relevant in vitro model that permits the interactions between
different cell types and ECM as described recently for mammary
epithelial and adipocyte co-cultures [29]. Other breast cancerous
3D models have been described recently in which malignant
breast cancer cells are embedded in reconstituted basement
membrane with direct co-culture of endothelial cells, enabling
investigation of the stimulatory effects of the latter cell type [30].
Suspension cultures such as spinner flasks have been investigated
but are often hindered by shear stress and turbulence [31] effects
experienced by the cells.
One method of generating 3D aggregates in a non-turbulent
environment and where cells secrete endogenous ECM and
growth factors is the Rotary Cell Culture System (RCCSTM),
originally developed by the National Aeronautics and Space
Administration (NASA) to study the effects of microgravity on cells
and tissues [32]. The system has been successfully used in tissue
engineering [33], developmental biology [34] and microbiology
[35]. The RCCS method has been extended to tumor cell
propagation (e.g. in prostate cancer [36] and colorectal cancer
[37]) where minimal shear force and continually suspended ‘free-
fall’ culture encourages cell aggregation. This permits biological/
biochemical processes to develop under closely monitored
environmental and operational conditions and encourages cells
to form 3D tissue-like aggregates which display physiologically
relevant phenotypes such as lower proliferation rate, hypoxic
regions and vasculature [1]. No previous publications have
specifically examined brain tumor growth in the RCCS or made
comparison between 2D culture, 3D culture and actual brain
tumor specimens. Analysis of gene expression, microRNA and
metabolic profiles demonstrates that our RCCS aggregates (in
comparison to 2D monolayer cultures) display a genotype
significantly more similar to actual brain tumors and may thus
replicate tumor behavior (e.g. response to therapeutic agents) more
faithfully. In addition, 3D aggregates can be cultured for at least
up to 4 weeks, compared to approximately one week in 2D
monolayer culture (due to cell confluency), providing a means to
assess drug efficacy and repeated dosing over a longer time period.
No artificial matrix or ECM components are introduced, allowing
cells to produce their own structures and with no artificial barriers
to drug diffusion. The increased size and heterogeneity of RCCS
aggregates compared to other culture methods e.g. neurospheres
or multicellular spheroids, increases their physiological relevance,
allowing drug testing against a simulation of an entire tumor
rather one selected cell line sub-clone as in 2D or neurospheres.
Critically, the RCCS aggregates display marked internal hetero-
geneity with separate populations of proliferative, senescent and
necrotic cells, influenced in part by the changing oxygen
concentration from rim to core of the aggregate. This uniquely
recapitulates the variety of in vivo environmental niches within
which cancer cells reside and which are now thought critical to
tumor development and progression.
Dynamic 3D Brain Tumor Culture
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In the present study, we sought to compare neoplastic histology,
morphology, proliferation rates, gene and microRNA expression,
metabolic profiles and histone deacetylase inhibitor sensitivity
between 2D monolayer cultures and 3D tumor cell aggregates
generated using the RCCSTM, in order to evaluate their relevance
for basic brain cancer disease modeling and pre-clinical drug
discovery. To our knowledge, this is the first comprehensive
molecular characterization of brain tumor aggregates cultured
using the RCCS, demonstrating considerable similarity in the
expression levels of key neoplastic genes to actual tumors and the
first report of RCCS drug sensitivity in comparison to 2D cultures.
Materials and Methods
Cell Lines – two and Three Dimensional Culture
The following established cell lines were utilized in the study –
KNS42 (pediatric GBM, a kind gift from C. Jones, Institute of
Cancer Research, London [38,39]), U87MG (adult GBM) [40,41],
PFSK-1 (pediatric central nervous system primitive neuro-
ectodermal tumor, purchased from ATCC [42]), DAOY (pediatric
medulloblastoma, purchased from ATCC [42,43]), GB1 (in-house
derived pediatric high grade glioma [42]), SF188 (pediatric
glioblastoma, [44,45]) and HBMEC (human brain microvascular
endothelial cell, a kind gift from Naveed Khan, University of
Nottingham, [46,47]). KNS42 were maintained in Dulbecco’s
modified Eagle’s medium (DMEM)/F12, U87MG, DAOY, C6
and GB1 in DMEM, PFSK-1 and HBMEC in Roswell Park
Memorial Institute (RPMI) medium 1640. All media were
supplemented with 10% (v/v) fetal bovine serum (except HBMEC
which were in 20% (v/v) fetal bovine serum), 100 IU/ml penicillin
and 100 mg/ml streptomycin. The same media were used for each
cell line in 2D and 3D culture and all culture took place in
a humidified incubator at 37uC and 5% CO2 atmosphere, except
the hypoxic controls for the Hypoxyprobe study which were
undertaken in a hypoxic chamber in a 1% O2 environment. 3D
culture utilized the Rotary Cell Culture System (RCCS)
(Synthecon, Luxembourg) situated within a cell culture incubator.
Culture was commenced by introducing 16106 cells as a single cell
suspension into a 10 ml culture vessel and initially rotated at 15
revolutions per minute (rpm). Once a visible aggregate formed,
revolution speed was adjusted to balance the Coriolis force against
gravity to maintain the aggregate in stationary freefall. Aggregates
were harvested at three weeks with media being changed twice per
week (50:50). Once harvested, aggregates were either fixed in 4%
(w/v) PFA or stored frozen at 280uC until required for further
analysis.
Preparation of RNA and Real Time PCR
Total RNA was isolated from cell pellets or aggregates using the
mirVana RNA isolation kit (Ambion, Austin,Tx). Reverse
transcription to cDNA (including genomic DNA elimination)
was performed using the RT2 First Strand Kit (SA Biosciences,
Frederick, MD). Array real time PCR was performed using the SA
Biosciences extracellular matrix and adhesion molecules PCR
array (PAHS-013A), analyzing 84 ECM related genes, 5 control
genes and positive and negative control wells (Table S1), using
a CFX96 real-time PCR machine (BioRad, Hercules, CA).
Validation real-time PCR for the genome wide data was
performed against the genes listed in Table S2. Primer efficiency
was calculated and the expression of each gene calculated relative
to normal adult brain RNA (FirstChoice, Ambion) using the
modified Pfaffl equation R= Etarget DCT (CT target gene control-
CT target gene sample)/Econtrol DCT (CT control gene control-
CT control gene sample) with GAPDH as the control gene.
Patients and Tissue Samples
The cohort of patient samples (n = 53) analyzed in the gene
expression array were a group previously published [4] with data
available online (GEO accession number GSE19578). All samples
were de novo pediatric high grade gliomas obtained ante mortem in
UK Neurosurgical centers with all diagnoses confirmed by central
pathological review. The cohort of samples analyzed for micro-
RNA expression (n = 77, 72 individuals) consisted of 21 samples
also analyzed in the gene expression cohort, with the other samples
also reviewed centrally and all of primary pediatric high grade
gliomas. Full consent and ethical approval has been obtained for
their use in this study, from the U.K. Children’s Cancer and
Leukaemia Group and local ethical and Trent MREC approval
(06/MRE04/86).
Gene Expression Array and MicroRNA Array
Gene expression analysis was performed on the Affymetrix
U133 plus2 platform, with triplicate experimental repeats for the
3D cultures. MicroRNA analysis was performed using the
Nanostring platform (Nanostring Technologies, Seattle, WA)
against 747 human and viral microRNA species (complete list of
probes and targets in Table S3).
Magnetic Resonance Spectroscopy (MRS)
Three week tumor aggregates were harvested, washed with PBS
and flash frozen in liquid nitrogen ensuring no trace of PBS or
media remained. Prior to NMR analysis, cell aggregates were
thawed at room temperature before being placed into 4 mm
zirconia rotors with 12 or 50 ml inserts depending on sample
volume. Any remaining volume in the rotor was filled with D2O
containing a trace of trimethylsilylproprionate-d4 to aid chemical
shift calibration. NMR analysis was performed on a Bruker HCD
hr-MAS probe with pulsed gradients available in the z-direction.
The probe operated at a magnetic field strength of 500 MHz
generated by an actively shielded Oxford Instruments magnet with
a 3-channel Bruker Avance II console. Sample spinning was set at
a rate of 4800 Hz and probe temperature was set to 278 Kelvin to
minimize metabolic activity. The NOESY-presat sequence was
used to suppress the water signal and 16K data points were
acquired at a spectral width of 16ppm following a 90 degree pulse.
Signal averages (256 or 512) were acquired, depending on the
signal to noise ratio of the sample, taking 14 or 28 minutes
respectively. Raw NMR data was processed using the TARQUIN
algorithm [48] to extract quantities for the following metabolites:
acetate (Ace); alanine (Ala); choline (Cho); creatine (Cr); glutathi-
one (Glth); glutamine (Gln); glutamate (Glu); glycine (Gly);
guanidinoacetate (Gua); glycerophosphocholine (GPC); hypotaur-
ine (h-Tau); myo-inositol (m-Ins); lactate (Lac); lipids (Lip); n-
acetylaspartate (NAA); phosphocholine (PCh); scyllo-inositol (s-
Ins); succinate (Suc) and taurine (Tau). Lac was removed from
subsequent analysis due to its high dependence on cell culture
media withdrawal. Metabolite profiles were normalized to their
sum and quantities were scaled to give equal variance. A heatmap
plot was generated with dendrograms on both axes calculated
using the complete linkage method.
Drug Testing and Alamar Blue Viability Assay
For 2D monolayer proliferation assays, U87 and KNS42 cells
were seeded onto wells of a 24-well plate at a density of 56104
cells per well. Alamar Blue proliferation assay was first
conducted 24 hours post-seeding (designated Day 1) and
conducted on three successive days subsequently. Briefly, media
was removed from the wells and cells washed twice with PBS to
Dynamic 3D Brain Tumor Culture
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ensure no trace of phenol red remained. Fresh PBS (1 ml) was
added to each well containing tumor cells followed by the
addition of 100 ml Alamar Blue indicator dye (Invitrogen, UK).
Following incubation for 2 hours at 37uC, 100 ml aliquots were
transferred to single wells of a 96-well black-bottom plate in
triplicate and fluorescence emission measured at 585 nm using
a plate reader (Tecan, Switzerland). Wells containing 2D cells
were replaced with fresh media and this procedure repeated on
Days 2, 3 and 4 in order to monitor proliferation of each cell
population over three days. For 3D culture proliferation assays,
U87 and KNS42 cells were cultured as RCCS aggregates at
10–15 rpm for 1 week. The following day was designated Day 1
of proliferation analysis and all subsequent proliferation readings
(arbitrary fluorescence units) were calculated relative to the Day
1 baseline reading, thus accounting for variations in aggregate
size after 1 week culture. 3D aggregates were removed from the
RCCS vessels and placed in single wells of a 24-well tissue
culture plate and washed twice with PBS. As above, 1 ml of
fresh PBS was added to each well containing an aggregate
followed by the addition of 100 ml Alamar Blue indicator dye
(Invitrogen, UK). Following incubation for 2 hours at 37uC,
100 ml aliquots were transferred to single wells of a 96-well
black-bottom plate in triplicate and fluorescence emission
measured at 585 nm using a plate reader (Tecan, Switzerland).
Tumor aggregates were subsequently returned to UV-irradiated
RCCS vessels and 3D culture resumed. This procedure was
repeated on Days 2, 3 and 4 in order to monitor real-time
proliferation of aggregates over three days. Data for all
proliferation analyses is presented as the average percentage
cell viability of three independent experiments with error bars
indicating standard error of the mean (SEM). For cytotoxicity
analyses of 2D monolayers, cells were seeded 24 hours prior to
drug treatment at a concentration range of 0–10 mM and the
Alamar Blue assay conducted after 72 hours drug exposure. For
cytotoxicity analyses of 3D cultures, cells were grown in the
RCCS for 1 week to allow aggregates to form, followed by
removal of the aggregates from the RCCS vessels and placing
in single wells of a 24-well plate. The Alamar Blue assay was
conducted as previously described and proliferation status at this
stage designated as baseline. Aggregates were returned to UV-
sterilized RCCS vessels and cultured in media containing
Vorinostat (Selleck Chemicals, 5 mM stock) at a concentration
range of 0–30 mM. Proliferation analyses were repeated after 72
hours drug exposure and data normalized to baseline readings
to take into account varied aggregate sizes due to stochastic
variation in the RCCS 3D culture.
Immunohistochemistry
Immunohistochemistry was performed according to previously
published protocols [49]. Aggregates were formalin fixed and wax
embedded prior to sectioning. Antigen retrieval was conducted by
steaming in citrate buffer for 40 minutes. Anti-Ki67 (Dako,
monoclonal mouse anti-human Ki67 antigen, clone MiB-1) was
applied for 30 minutes at room temperature at 1:50 concentration.
Anti-beta galactosidase (Abcam, mouse monoclonal DC1 4C7)
and anti-CDKN2A/p16INK4a (Abcam, mouse monoclonal
2D9A12) were utilized at 1:1000 and 1:800 concentrations
respectively for one hour at room temperature. Secondary
antibody (100 ml Dako horse radish peroxidase conjugated rabbit
anti-mouse) was applied for thirty minutes at room temperature
before application of 3,39-Diaminobenzidine chromogen. Positive
control tissues were tonsil (Ki67) and colon carcinoma (beta-
galactosidase and p16). Immunohistochemistry for Ki67, p16 and
beta-galactosidase was scored by counting positive nuclei as
a percentage of total nuclei within multiple high powered fields (at
least three for each specimen). For tumor specimens on the tissue
microarrays, the most positive area (‘hot-spot’) for each core was
scored. For cell cultures undergoing hypoxyprobe (Hypoxyprobe
Inc., Burlington, MA) analysis, the hypoxyprobe reagent (pimo-
nidazole) was applied two hours before harvesting at 200 mM
concentration. Samples were then fixed as standard and immu-
nohistochemistry performed using the primary antibody supplied
with the hypoxyprobe kit at 1:200 concentration. Positive controls
were performed using 2D cell cultures cultured in a hypoxic
chamber at 1% atmospheric oxygen. Negative controls were
performed by omitting the primary antibody and also with
monolayer cells cultured in 21% oxygen, 5% CO2 atmospheric
conditions.
Immunofluorescence
Monolayer cells or 3D RCCS aggregates were fixed in 0.4%
paraformaldehyde and blocked in 5% normal goat serum/0.1%
Triton-X for 1 hour at room temperature. For immunolabelling,
cells were incubated with anti-beta galactosidase (Abcam, mouse
monoclonal DC1 4C7) using a 1:1000 dilution overnight at 4uC in
a humidified chamber. Cells were washed and incubated with the
anti-mouse Alexa-fluor 555 (Dako) using a 1:300 dilution in the
dark at room temperature. Nuclei were visualized using DAPI and
fluorescence signals were recorded using a Leica DMRB upright
fluorescent microscope.
Scanning Electron Microscopy
Three dimensional tumor aggregates were washed three times
in fresh PBS and fixed in 3% glutaraldehyde for 12 hours. Fixed
samples were then washed three times in PBS and dehydrated for
a further 12 hours by exposure to air at room temperature. Fixed
and dehydrated aggregates were mounted on aluminum stubs and
were sputter-coated with gold at an argon current rate of 30 mA
for 3 minutes. Cell morphology and organization in the aggregates
was visualized using a scanning electron microscope (SEM) (JEOL
JSM-6060LV) at 10 kV.
Biostatistical Analysis
Analysis of gene expression and microRNA array data was
conducted using the Genespring package (Agilent, UK) with
comparison between groups performed using unpaired two-tailed
t-test with Benjamini-Hochberg multiple test correction. Analysis
of the array PCR data was undertaken using the accompanying
Excel based statistical package (SABiosciences). Pathway analysis
was performed using the Ingenuity IPA package (Ingenuity
systems). SPSS software was used to conduct student t-test and P
values were considered significant at less than 0.05 throughout.
Results
Macroscopic 3D RCCS Aggregates Recapitulate the
Heterogeneous Morphology of Primary Brain Tumors
Visible macroscopic cell aggregates were observed after 24–48
hours of initiating culture and achieved maximal size after one
week of culture. Diameter of aggregates was broadly consistent for
each cell line utilized but varied between different cell lines. The
largest aggregates resulted when using the PFSK-1 cell line at up
to 9 mm diameter and KNS42 (up to 5 mm). U87 formed
multiple (5–10) smaller aggregates each 1–3 mm in diameter.
Cultured aggregates were maintained viable in culture for up to six
weeks, but were typically harvested at three weeks for molecular
and cellular characterization.
Dynamic 3D Brain Tumor Culture
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Aggregates from all cell lines had similar overall reproducible
morphology with a highly cellular rim (typically 100–200 mm
thick) of viable cells, an intermediate transitional zone of mixed
healthy and dying cells and a central core of low cellularity with
the majority of cells necrotic or apoptotic (Figure 1 A–H). For the
derived GB-1 cell line, comparison was possible with the original
primary tumor and this demonstrated very similar morphology
and cellular growth density with a mean of 424 cells per high
powered field (hpf) for the primary tumor and 398 cells per hpf for
the 3D aggregate (no statistically significant difference, p= 0.452)
(Figure 1 I–J). The 3D aggregates also resembled tumors in their
re-capitulation of heterogeneity with high and low cellularity
regions. The high cellularity rim and low cellularity core was also
visualized with scanning electron microscopy with secreted
extracellular matrix elements observed as the 3D aggregates
began to lay down endogenous ECM (Figure 1 K–L). In contrast,
GB-1 2D monolayer cells display a more homogeneous morphol-
ogy throughout the culture vessel with no distinct regions spatially
(Figure 1M).
RCCS Aggregates Display Cellular Heterogeneity and
Reduced Proliferation Rates
Immunohistochemistry for Ki67 revealed the great majority
of proliferative cells in 3D aggregates to be within the rim or
transitional zone, with no or very few positive cells in the
central core (Figure 2 A–C). The exact pattern of staining
varied slightly between cell lines but all lines exhibited these
general characteristics. Staining for p16 and beta-galactosidase,
markers of cellular senescence, exhibited similar results, whereby
both antibodies stained a much higher proportion of cells within
the core as compared to the rim. For the KNS42 line, P16
stained 90% of cells in the core and 40% of cells in the rim,
whereas beta-galactosidase stained 47% in the core and 1% in
the rim. This pattern was repeated for all the other cell lines
(data not shown). Both P16 and beta-galactosidase showed
a similar proportion of positive staining in the core of primary
tumors compared to the core of 3D aggregates (Figure 2 D–I).
Immunohistochemistry for these targets was also performed
against our cohort (n = 150) of pediatric high grade glioma
Figure 1. Morphology and cellular heterogeneity of RCCS aggregates. A–D – Low power views of sections of formalin fixed paraffin
embedded GB1, U87, DAOY and PFSK-1 aggregates respectively, demonstrating low cellularity necrotic core and densely cellular proliferative rim. E–
H – High power views of GB1, U87, KNS42 and PFSK-1 respectively, demonstrating cellular heterogeneity at the rim/core interface and necrotic tissue
with apoptotic figures in the core. I&J – GB1 aggregate and sample of primary tumor from which cell line was derived respectively demonstrating
similarity in cellular morphology and growth density. K&L – Scanning electron microscopy of GB-1 RCCS aggregates with dense rim and exposed
core in K and high powered surface view in L. M – Morphology of GB-1 2D monolayer cells. Scale bars 100 mm in A–D and 25 mm in E–J and M.
Magnification6500 in K and62000 in L.
doi:10.1371/journal.pone.0052335.g001
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archival specimens on tissue microarrays. We found a statistically
significant association between Ki67 staining in perivascular
areas and patient survival as previously reported [49]. No
significant correlation was found between p16 staining and
survival (p = 0.577 Cox regression) and only a weak trend to
better survival with elevated numbers of cells positive for beta-
galactosidase (p = 0.161 Cox regression, p = 0.09 Logrank).
Interestingly, cells that were positive for senescence markers
(typically regarded as a tumor specific characteristic) were
observed in the vessel wall and even within the endothelial
lining (Figure 2I). Beta-galactosidase staining indicative of
cellular senescence was clearly defined around the peri-necrotic
region of KNS42 aggregates (Figure 2J) whereas no positive
staining was evident in either KNS42 or U87 2D monolayers
(Figure 2K–L). Proliferation assays demonstrated significantly
reduced rates of proliferation in 3D cultures of KNS42 and
U87 compared to the same cell lines cultured in 2D monolayers
(p,0.05) (Figure 2 M–N). Relative growth over three days in
3D cultures was 27% and 38% of the 2D growth rates for U87
(population growth from day 0 (100%) was 266% vs. 982%)
and KNS42 (population growth from day 0 (100%) was 159%
vs. 420%) respectively.
Co-culture of HBMEC brain endothelial cells with KNS42
cells had marked effects on aggregate cellular morphology
(Figure 3 A and C). The necrotic core of aggregates was
substantially reduced in size compared to monoculture of the
KNS42 line alone, with numerous tubular structures also
apparent. Cells positive for the endothelial marker von Will-
ebrand factor (vWF) were intermingled with negative cells in the
viable rim area. Hypoxyprobe staining demonstrated consistent
and specific staining on 2D monolayer cells cultured under
hypoxia (1% oxygen atmosphere). The hypoxyprobe system
utilizes cellular metabolism to produce the pimonidazole
molecule targeted by immunohistochemistry, where only viable
cells stain positive. Dead or dying cells cannot produce the
active metabolite and thus remain unstained, although the
oxygen tension may be low in that area. On staining of 3D
aggregates, a band of staining in the transitional zone between
rim and core was observed, suggesting this as a region where
the cells were under hypoxic strain but still viable (Figure 3 D–
G). The cores were generally negative, suggesting cells here
were either dead or unable to metabolize normally.
Microenvironment of RCCS Aggregates Consists of
Upregulated Endogenous ECM
Analysis of 84 ECM related genes by array real-time PCR
demonstrated significant changes in the expression levels of many
genes. The differential patterns of expression between the same
cell lines cultured in 2D and 3D are illustrated in Figure 4. Genes
significantly upregulated in 3D culture included matrix metallo-
proteinases, transforming growth factor beta (TGF-b), cell
adhesion molecules (CAM) and integrins. Genes downregulated
included collagen subtypes, tissue inhibitors of metalloproteinases
(TIMPs) and thrombospondin 1. A full list of differentially
expressed genes is provided in Table S4. Immunohistochemistry
was used to validate the upregulated expression of ICAM-1 in 3D
relative to 2D culture (Figure S1).
Genome Wide Expression in RCCS Aggregates is
Intermediate to 2D Cultures and Primary Tumors
Genome wide gene expression analysis revealed significant
numbers differentially expressed transcripts between 2D mono-
layer and 3D RCCS cultures. Comparison between 3D and 2D
culture of the U87 adult GBM line demonstrated 19365 probes
significantly differentially expressed (10159 probes upregulated
and 9206 probes downregulated in 3D compared to 2D)
accounting for 13116 unique gene expression profiles. The top
20 differentially expressed genes by fold change are listed in
Table 1 with a full list of differentially expressed probes in Table
S5. Transcripts with highest differential expression in U87
included several genes proposed to be involved with stem cell
self renewal and differentiation, e.g. SOX2 and growth factor
pathway genes, e.g. EREG and NEDD9. For KNS42 1771 probes
were differentially expressed (969 upregulated and 802 down-
regulated in 3D compared to 2D), representing 1386 unique gene
expression profiles. The most differentially expressed genes for
KNS42 are also listed in Table 1 with a full list of differentially
expressed probes in Table S6. Highly differentially expressed
genes for KNS42 included multiple chemokines, interleukins and
ECM modifiers. Genes highly differentially expressed in a similar
fashion in both U87 and KNS42 included KYNU, IL1B and
CXCL12.
On comparison between 3D cultures, 2D cultures and primary
tumor specimens, expression levels of numerous genes were
significantly more similar between 3D and the primary tumor set
than between 2D and the primary tumor set (p values ,0.05). The
20 genes most differentially expressed between 2D culture and
primary tumors are listed in Table 2. The expression of all bar one
of these genes is more similar in 3D culture when compared to the
expression level seen in primary tumors. The full list of all genes
significantly differentially expressed between 2D, 3D and primary
tumors is included in Table S7. Many genes already implicated in
cancer and high grade glioma in particular are included in Table 2,
e.g. PTPRZ1 and SOX2. Other genes have clear links to neuronal
and astrocytic development e.g. TUBB2B and FABP7. In total
2604 genes had fold changes two or more times more similar to
primary tumor in 3D compared to 2D. 818 genes were two or
more times more similar to primary tumor in 2D compared to 3D.
Ingenuity analysis of the differentially expressed genes for U87
demonstrated that the top physiological functions associated with
these genes included nervous system development, embryonic
development and connective tissue development. The same
analysis for KNS42 suggested that tumor and tissue morphology
functions are implicated the most. Genome wide profiling of the
3D cultures in general demonstrated gene expression profiles
intermediate between 2D monolayer cultures of the same cell lines
and a large cohort of pediatric high grade gliomas, clustering next
to the actual tumors on unsupervised hierarchical clustering
analysis (Figure 5). The intermediate nature of the 3D culture
genetic profile is evident through principal components analysis of
U87 3D culture, U87 2D culture and the tumor cohort, with the
3D culture clustering between the monolayer samples and the real
tumors. The genetic changes observed in the genome wide analysis
were validated on gene specific realtime-PCR for selected genes as
shown in Figure 5.
On analysis of the microRNA profile using the Nanostring
platform a similar pattern of results was demonstrated. Cell lines
cultured in 3D displayed a profile intermediate between actual
tumors and the 2D monolayer cell line cultures. This relationship
is demonstrated in the unsupervised clustering dendrogram
(Figure 5). MicroRNAs most differentially expressed included
miR-630 (4.2 fold increased expression in 3D cultures), miR-1308
(3.9 fold downregulated in 3D) and miR-19b (3.7 fold down-
regulated in 3D).
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Figure 2. Heterogeneous cellular phenotypes and reduced proliferation rates of RCCS aggregates. A–C – Immunohistochemistry
against Ki67 for U87, PFSK-1 and primary HGG respectively demonstrates proliferative cells in the rim and/or rim/core interface of aggregates at
similar frequencies to primary tumor. D–F – Immunohistochemistry against P16 in a KNS42 aggregate core (D), KNS42 rim (E) and in a primary HGG
(F) showing a higher proportion of cells staining positive in the aggregate core compared to the rim and which is comparable to the primary tumor.
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G–I – Immunohistochemistry against beta-galactosidase in a KNS42 aggregate core (G), KNS42 aggregate rim (H) and in a primary HGG (I) showing
that significant staining for senescence markers occurs in both resected tumors and aggregate cores. J–L – Immunofluorescence against beta-
galactosidase in KNS42 aggregates, KNS42 2D monolayer cells and U87 2D monolayer cells. M&N – Alamar Blue assay proliferation rates in U87 (J)
and KNS42 (K) comparing 2D and RCCS culture demonstrating significantly decreased proliferation in 3D compared to 2D for both cell lines. Scale
bars in A–I and K–L are 25 mm. Scale bar in J is 100 mm.
doi:10.1371/journal.pone.0052335.g002
Figure 3. RCCS aggregates exhibit heterogeneous oxygen tension. A – Co-culture in RCCS of KNS42 and HBMEC brain endothelial cells
demonstrating a reduced necrotic core compared to pure KNS42 culture (B). C – High powered view of rim of co-culture stained positive for von
Willebrand factor with mixed cell morphologies. D – KNS42 2D monolayer culture grown with hypoxyprobe in normoxia (21%) with no positive
staining. E – KNS42 2D monolayer culture grown with hypoxyprobe in 1% oxygen showing widespread positive staining. F – U87 aggregate cultured
in RCCS (21% oxygen) demonstrating positive staining in deep hypoxic rim with no staining in normoxic peripheral rim or in fully necrotic core. G –
KNS42 aggregate showing positive staining in cells deep within the aggregate rim adjacent to the necrotic area. Scale bars 100 mm in A, B and F;
25 mm in C, D, E and G.
doi:10.1371/journal.pone.0052335.g003
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Differential Metabolic Profiles Evident through RCCS and
Monolayer Culture
Magnetic resonance spectroscopy reveals distinct metabolite
profiles of U87, KNS42 and PFSK-1 cells grown in 2D and 3D
conditions. Three replicates were prepared and analyzed to assess
reproducibility. A clear clustering of the 2D and 3D samples
demonstrates that the culture method represents the greatest
source of influence on the metabolic profile. Subsequent levels of
clustering show the close grouping of replicates from the same cell
line, making this the second greatest source of influence on the
metabolic profile (Figure 6 A–B). The 3D culture method shows
a consistent increase in lipids, myo-inositol and glycine with
a reduction in phosphocholine for each line relative to the 2D
cultures (Figure 6C).
RCCS Glioblastoma Aggregates Demonstrate Reduced
Sensitivity to Histone Deacetylase (HDAC) Inhibition
Aberrant HDAC expression has been linked conceptually and
mechanistically to the pathogenesis of cancer due to perturba-
tion of acetylation-deacetylation homoeostasis. As such, a num-
ber of HDAC inhibitors (HDACi) are under pre-clinical and
clinical investigation as viable anticancer agents [50,51].
Promising in vitro results has lead to several brain tumor clinical
trials using HDACi, with a Vorinostat phase II trial in adult
recurrent glioblastoma multiforme showing anti-cancer activity
[52] and a Vorinostat phase I trial in synergy with 13 cis-
retinoic acid, recently completed for pediatric medulloblastoma
and CNS primitive neuroectodermal tumors [53]. We hypoth-
esized that RCCS derived aggregates would render brain tumor
cells less sensitive to Vorinostat compared to 2D monolayers as
proof-of-concept of reduced drug sensitivity within the 3D
tumor microenvironment. U87 and KNS42 glioblastoma mono-
layer cells were exposed to an acute Vorinostat dose (0.5 mM–
10.0 mM) for three days and assessed for metabolic activity
thereafter. Both cell lines broadly exhibited dose-dependent
sensitivity to Vorinostat with an IC50 of 5 mM and 1 mM for
U87 and KNS42 respectively (Figure 7A and C). Based upon
our prediction of reduced drug sensitivity in 3D culture, we
exposed one week 3D U87 and KNS42 cultures to Vorinostat
concentrations of 5 mM, 10 mM and 15 mM. To control for
stochastic variations with respect to aggregate size after one
week in RCCS culture, we normalized metabolic activity after
72 hours drug treatment to metabolic activity after 0 hours (i.e.
point at which macroscopic aggregates had formed and prior to
drug exposure). For both untreated and drug treated samples,
the same aggregate was assessed at 0 and 72 hours for
metabolic activity. Due to an observed reduction in viability in
the 3D KNS42 untreated culture (Figure 7D), most likely due to
necrosis in the aggregate core being greater than proliferation in
Figure 4. Upregulation of endogenous ECM in RCCS aggregates. Volcano plot of 84 ECM associated genes comparing expression after
culture in 2D or 3D with upregulation in 3D shown as a positive fold change. Light grey vertical lines represent a fold change of +/23 fold and the
light grey horizontal line represents a p-value of 0.05. Selected significantly differentially expressed genes are labeled. Table lists top 5 (by fold
change) significantly up- and down-regulated genes for each cell line. Three independent aggregates were used for each cell line and three ECM PCR
arrays were conducted for each aggregate.
doi:10.1371/journal.pone.0052335.g004
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the rest of the aggregate, KNS42 3D drug treated cultures were
further normalized to the proportion of KNS42 untreated cells
that were viable only. Both high grade glioma cell lines
demonstrated significantly reduced sensitivity to Vorinostat with
IC50 of 12.5 mM and 13.5 mM for U87 and KNS42 respectively
(p value ,0.05) (Figure 7B and D). This amounts to a 2.5 fold
reduction in Vorinostat sensitivity in U87 and a 13.5 fold
reduction in KNS42 when assaying in 3D culture conditions
(Figure 7E).
Primary Explant Culture in the RCCS Retains Features of
the Primary Brain Tumor
Primary glioma tumor explants were taken directly from the
operating theatre and placed into the RCCS. Culture in standard
medium was maintained for 3 weeks, with the gross structural
integrity of the explant preserved. Explants began to develop
a necrotic core and viable rim in a similar fashion to cell line
derived aggregates. Additional features of internal histology were
preserved from the primary tumor, including heterogeneity and
cells staining positive for endothelial markers in blood vessel walls.
Explants demonstrated positive Ki67 staining after 3 weeks of
culture but at lower levels than the proliferative areas of actual
primary tumor (Figure 8). A conventional 2D monolayer cell line
was derived from an adult GBM tumor and comparison with
a sample of the same tumor cultured for three weeks as an explant
made using the ECM real-time-PCR array. There was significant
variation in gene expression between the two samples with genes
such as ITGB2, KAL1, MMP 8/9/12, NCAM1 and SPP1
upregulated significantly in the explant and THBS1, CTGF,
COL1A1 and COL14A1 expressed at significantly lower levels (P
values,0.05) in the explant (data not shown).
Discussion
Although the clinical trial will remain the ultimate testing
ground for evaluation of novel next-generation anti-cancer
therapies, these are expensive with a myriad of logistical,
regulatory and ethical considerations. Therefore, representative
preclinical model systems that are both laboratory and computa-
tional based, need to provide an intermediate testing ground for
experimental agents. However the long history of use of 2D cell
panels such as the NCI-60 has often proved relatively poor at
predicting both in vivo animal model and early phase clinical trial
efficacy and toxicity. The limitations of relating 2D cell panels to
clinical tumors is due to a tumor microenvironment far removed
from the physiological setting, inaccurate drug uptake and altered
pharmacokinetics/pharmacodynamics of the selected drug(s). The
present study provides a comprehensive characterization of the
RCCS as a method of cancer cell culture to generate a tumor
niche more physiologically relevant than 2D culture and drug
response more representative of clinical high grade brain tumor
drug response, than conventional 2D cell panels.
It is increasingly clear that cancer is a process involving complex
interactions between tumor cells and the surrounding microenvi-
ronment, including non-neoplastic cells, ECM and environmental
conditions such as oxygen tension [54,55]. Critically, these
conditions vary within different regions of high grade brain
tumors with a characteristically hypoxic necrotic core; an in-
termediate zone where cells survive but under hypoxic strain and
the periphery of the tumor where cancer cells invade into relatively
Table 1. Top twenty genes by fold change differentially expressed between 2D and RCCS culture.
U87 KNS42
Gene Fold change 3d vs. 2d
Corrected
p value Gene Fold change 3d vs. 2d Corrected p value
GPM6B 572.66 1.13E209 CCL20 619.68 0.005
IGFBP5 433.33 2.57E210 IL8 210.72 0.006
SOX2 409.13 4.19E212 PTGS2 88.61 0.010
SOX2OT 372.92 1.89E211 SOD2 72.32 0.004
PTPRZ1 353.69 4.91E210 EREG 70.47 0.010
TFPI2 2351.24 3.35E210 IL1B 65.92 0.005
NEDD9 340.64 1.09E211 CHI3L1 64.71 0.012
EPHA3 326.63 4.82E214 TNFAIP6 32.12 0.008
MGP 304.67 4.36E207 CXCL2 31.69 0.005
TOX3 299.67 7.16E214 MMP1 29.71 0.032
GPM6A 272.30 4.57E208 IL1A 24.40 0.005
CNR1 243.90 8.15E210 FLG 223.13 0.011
NID1 208.49 1.74E208 IER3 20.94 0.010
EDNRB 203.30 3.39E210 IL11 20.90 0.021
POSTN 176.93 2.90E207 IL6 20.67 0.011
EREG 2166.10 1.02E207 GRM1 20.19 0.013
DKK1 161.32 2.54E209 EHF 20.08 0.016
SORL1 153.42 4.34E210 SERPINB2 16.43 0.014
ODZ2 153.08 2.17E207 CCL8 15.98 0.013
KYNU 2147.83 2.11E209 ID3 215.53 0.010
doi:10.1371/journal.pone.0052335.t001
Dynamic 3D Brain Tumor Culture
PLOS ONE | www.plosone.org 10 December 2012 | Volume 7 | Issue 12 | e52335
well oxygenated brain. Models have been proposed whereby this
heterogeneity of conditions gives rise to different sub-populations
of tumor cells which fulfill different functions and niches within the
tumor as a whole. Much interest has focused on the immediate
vicinity of small tumor associated blood vessels within the brain,
termed the microvascular niche, as a possible favorable habitat for
the stem-like cells which may be critical in tumor propagation and
resistance to treatment [56,57]. It may be that different areas of
the tumor may favor other sub-clone populations such as
proliferative or invasive cells. Monolayer cell culture creates
a relatively homogeneous population of cells that are all subject to
the same selection pressures. Heterogeneity between different
areas within the same tumor has long been recognized histolog-
ically, but has also now been demonstrated molecularly with
different driving genes amplified in different areas of a glioblastoma
[6]. This heterogeneity may partially explain the failure of targeted
therapies, with only a subset of tumor cells being potentially
sensitive to a particular compound. The RCCS model recapitu-
lates heterogeneity histologically, allowing more representative
drug testing against the entirety of a tumor rather than solely the
proliferative fraction present in a 2D monolayer.
Monolayer cell culture typically takes place in room air (21%
oxygen content) with supra-physiological concentrations of glucose
and other metabolites in the feed medium. The normal brain
oxygen saturation is around 7% with tumor regions ranging from
5% to less than 1% [58]. Cell culture can be performed in
a hypoxic chamber, though this still does not replicate the gradient
in oxygen concentration seen in tumors in vivo. Previous studies
have demonstrated that the oxygen concentration to which cells
are exposed is of critical importance in defining the behavior of
those cells in high grade brain tumors [59,60,61]. This may have
direct therapeutic implications in areas such as the derivation of
dendritic cell based anti-cancer vaccines. It also seems that the
gene expression profile of tumors is affected by region, with
biopsies taken from more ischemic/necrotic regions displaying
a more mesenchymal genotype [62]. The behavior of cancer stem-
like cells is also known to be profoundly impacted by their
environmental oxygen levels [63,64,65]. Many processes involved
in the development of CNS tumors are also by definition 3D such
as angiogenesis and interaction with the ECM. Again, these
processes are not re-capitulated in 2D culture which is a highly
reductionist model. We have demonstrated that an oxygen
gradient exists across the RCCS aggregates replicating a key
feature of the environmental conditions to which brain tumors are
exposed. This seems likely to have implications for cell behavior
within the culture model, crucially replicating the exposure of
different areas of the cell population to different conditions within
the same tumor. Members of our group have previously
demonstrated similar findings in breast cancer where the hypoxic,
relatively harsh micro-environment seems to select for a more
aggressive metastatic phenotype [66].
In vivo animal models typically consist of xenotransplantation of
a human cancer cell line into an immunocompromised rodent
host. Orthotopic grafting replicates many facets of the CNS
environment in which human tumors develop and some processes
such as development of a vascular network. However, these
Figure 5. Gene and microRNA expression in RCCS aggregates resembles an intermediate phenotype between 2D cultures and
primary tumors. A – Clustering dendrogram of significantly differentially expressed probes from Affymetrix U133 plus2 gene expression analysis
between U87 and KNS42 2D cell cultures, 3D cell cultures and a cohort of pediatric high grade gliomas with 3D profiles clustering intermediate to 2D
and actual tumors, also demonstrated for the U87 3D cultures in a principal components analysis (B). C – Unsupervised clustering dendrogram
performed on Nanostring microRNA profiles, demonstrating 3D samples generate a profile intermediate to 2D cultures and actual tumors. D –
Realtime PCR validation for selected genes of the gene expression array data, showing significantly elevated levels of PTPRZ1, SOX2 and S100B in 3D
compared to 2D culture for U87 cells.
doi:10.1371/journal.pone.0052335.g005
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models all have a rodent host as their basis and the disappointing
record of therapeutic agents taken into phase I/II trials following
animal studies demonstrates how specific tumor/host environment
interactions are critical in governing tumor behavior. It is as yet
unclear whether, for example, interactions between tumor and
endothelial cells are species specific. The immune system (known
to have a key role in human brain tumors) in these animals also
behaves very differently to that in a normal human, further
reducing the strength of animal models. Animal experiments have
other drawbacks such as their cost and the ethics of utilizing large
numbers of animals in research with an increasing pressure to
reduce the use of animals in research and drug development.
Other 3D models have been used to try and overcome these
issues and the most widely used of these in cancer and stem cell
research is the non-adherent neurosphere culture. It is well
recognized that this culture method increases the proportion of
cells displaying stem-like properties and markers [67]. Other
advanced culture methods used to model tumor growth include
the hanging drop method (creating similar entities to neuro-
spheres) [68], hollow fibers [69], microfluidic chambers and
multicellular layer constructs [70]. The latter three methods still
utilize support membranes or fibers which provide an artificial
physical contact point for cells and do not replicate true
unrestricted growth in 3D. Neurospheres range in size from
around 50 mm to a maximum of around 300 mm in diameter
(compared to 1–9 mm for RCCS aggregates). At their largest size
they begin to exhibit a necrotic core [71] in a similar fashion to
RCCS aggregates, though the effect is significantly less pro-
nounced. Neurosphere culture generally involves culture media
that differ from the standard preparations used for monolayer
culture; for example neurosphere medium is usually serum free
and supplemented with epidermal growth factor and basic
fibroblast growth factor. The RCCS aggregates are formed in
the same medium as used for 2D cell culture, thus removing the
influence of media composition on comparisons between RCCS
and 2D culture using the same cell line. The recent demonstration
of a 3D culture system with automated and quantitative analysis,
similarly generates tumor spheroids with a size range of 300–
500 mm in diameter [24]. Although matrix invasion and
angiogenic differentiation was induced when tumor cells were
co-cultured with embryoid bodies, we believe that the ,10-fold
larger RCCS aggregates display more acute cellular heterogeneity
with clearly delineated proliferating rim, necrotic core and peri-
necrotic rim with direct observation of hypoxic stress and
senescent cells in this region. Indeed we have also shown that
a proportion of RCCS brain tumor aggregates exhibit a vasculo-
genic phenotype and angiogenic gene expression profile in the
absence of any form of co-culture, a phenomenon termed
‘vasculogenic mimicry’ (Smith et al, manuscript in preparation).
Moreover as the immediate tumor microenvironment is generated
by the secretion of endogenous ECM rather than exogenous and
artificial substrates, the resulting paracrine signaling and resulting
global gene expression changes in the RCCS may be more
informative than other 3D methods. In support of the importance
of cancer cell-ECM interactions with regards to mimicking
physiological aspects of tumor biology, Loessner and colleagues
describe a 3D culture consisting of a sophisticated synthetic
hydrogel matrix with incorporated biomimetic features. This
method permitted exposure to similar biochemical and bio-
mechanical stimuli in all directions due a homogenous dispersion
Table 2. Differentially expressed genes amongst U87 2D/3D culture and primary HGG.
Gene
Fold change([2D]
vs. [Tumor])
Fold change([RCCS]
vs. [Tumor])
Ratio FC 2d:3d to
primary tumor
Corrected
p-value
PTPRZ1 2491.37 21.60 307.65 3.78E209
GPM6B 2471.23 1.15 410.33 3.80E213
SPARCL1 2391.25 211.30 34.63 6.16E208
GFAP 2364.51 298.91 3.69 4.43E215
TFPI2 342.55 1.06 322.65 1.79E206
PMP2 2302.93 216.77 18.06 9.02E206
AQP4 2284.39 2339.70 0.84 2.76E206
GPM6A 2242.65 21.07 227.83 5.35E209
SOX2 2223.37 1.56 143.57 1.01E221
ABAT 2212.84 237.53 5.67 2.82E207
HSPA1A 2161.45 242.70 3.78 2.94E207
TUBB2B 2136.40 21.92 71.17 4.38E211
EREG 122.55 21.05 116.34 5.60E208
OLIG1 2121.24 2103.53 1.17 1.79E205
ATP1A2 2120.92 285.93 1.41 1.12E205
SEPP1 2117.92 23.44 34.26 2.19E207
KYNU 106.24 21.21 88.07 4.80E210
DKK3 2105.00 1.19 88.59 8.06E215
SLC1A2 2104.62 278.97 1.32 4.55E208
C13orf15 2102.58 217.84 5.75 2.90E206
The twenty genes most differentially expressed between 2D culture of U87 and primary HGG with the comparative fold change between RCCS culture of U87 and HGG
for each gene. The ratio of the fold changes indicates greater similarity between RCCS culture and primary tumor if greater than one and greater similarity for 2D culture
if less than one.
doi:10.1371/journal.pone.0052335.t002
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of ovarian tumor cells. Importantly, increasing matrix stiffness
inhibited spheroid growth resulting in a more compact spheroid. A
recent high-throughput automated 3D culture system based upon
microfluidic channels similarly permits the generation of homog-
enous and densely packed tumor cell aggregates in a reproducible
manner, resulting in increased drug resistance compared to 2D
cultures. These findings implicate cell density, cell-cell interactions
and cell-ECM interactions as contributing mechanism by which
the proliferation rate of cells in 3D may be relatively slower than
corresponding 2D cultures and additionally why 3D cultures may
be relatively more drug-resistant [72,73]. We have profiled the
same cell lines after culture in 2D and 3D RCCS, demonstrating
statistically significant differences in the expression levels of many
key genes known to be involved in the neoplastic process.
Profound changes take place between 2D and 3D in the expression
of genes involved in areas such as ECM, cell proliferation and
stem-like characteristics. These changes alter the overall genetic
profile of the sample, rendering them significantly more similar to
the profiles exhibited by our cohort of primary pediatric high
grade gliomas, though there are clearly still differences between
3D cultures and clinical tumors. Investigation of agents targeting
specific molecular pathways is again likely to be more efficacious in
model systems such as the RCCS which more closely replicates
gene expression and protein activity levels observed in clinical
Figure 6. RCCS aggregates and 2D monolayers exhibit distinct metabolic profiles. A – Heatmap dendrogram of the HR-MAS metabolic
profiles generated for KNS42, U87 and PFSK1 cell lines grown in 2D and 3D, showing clustering together of replicates grown by the same culture
method with metabolites on the x-axis and samples on the y-axis. B – Principal components analysis of the HR-MAS data demonstrates further clear
clustering by cell type and culture method. C – Barplot of metabolite levels for the three cell lines, comparing 2D and 3D culture averaged across
three replicates for each sample with standard error bars, demonstrating significant differences for many metabolites between culture methods with
consistent increases in lipids, myo-inositol and glycine and decreased phosphocholine in 3D for all cell lines.
doi:10.1371/journal.pone.0052335.g006
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tumors. Sensitivity to drugs will depend upon the exact expression
levels of many genes and it is clear that radically different and less
meaningful results are likely to be achieved in drug testing using
2D compared to 3D culture.
Similar results are observed when considering the metabolic
profiles generated by the in vitro MRS analysis performed. Culture
method was found to be the most important factor in generating
the metabolic profile and samples cluster accordingly. Lipids are
consistently increased in 3D compared to 2D culture, which
typically represents increased levels of cell death, accurately
reflecting the changes observed in the histology of aggregates with
their necrotic centers. Elevated lipid peaks are also typically
observed in necrotic regions of actual high grade brain tumors,
especially glioblastomas [74]. The decreased phosphocholine
observed in 3D culture is consistent with slower growing cells
such as observed in vivo after chemotherapy [75] which provides
metabolic corroboration of the proliferation rates observed in our
study. Moreover a recent study provides evidence that homo-
eostasis in 3D tumor aggregates is achieved through a balance
between cell proliferation, growth arrest and cell death [76],
supporting the recapitulation of heterogeneous tumor sub-popula-
tions within 3D systems as described here. Increased myo-inositol
and glycine may correspond to higher grade behaviors within
Figure 7. RCCS glioblastoma aggregates demonstrate reduced drug sensitivity. U87 and KNS42 glioblastoma cultures (monolayer or RCCS)
were treated with Vorinostat for 72 hours prior to assessment of proliferation using the Alamar Blue assay. A – U87 2D cells show dose-dependent
sensitivity to Vorinostat with an IC50,5 mM. B – U87 aggregates generated using the RCCS are less sensitive to Vorinostat with an IC50,12.5 mM. C –
KNS42 2D cells show acute sensitivity to Vorinostat with an IC50 ,1 mM. D – KNS42 aggregates generated using the RCCS are markedly less sensitive
to Vorinostat in comparison with an IC50 ,13.5 mM. E – Mean IC50 values calculated from A–D. Drug treatment data on 2D monolayer cultures are
expressed as percentage viability relative to untreated cultures and presented as the mean of three independent experiments with standard error of
mean shown. Drug treatment data on 3D aggregates are presented as the mean of two independent experiments that are normalized to Alamar Blue
readings of each culture immediately prior to drug exposure with standard error of mean shown.
doi:10.1371/journal.pone.0052335.g007
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tumors [77] and their elevation in 3D compared to 2D culture is
intriguing and warrants further investigation.
Resistance to chemotherapeutic drugs has been shown to differ
significantly for cell lines grown in vivo, in neurospheres or in
monolayers [78,79,80,81,82]. Resistance is generally highest in vivo
and lowest in 2D, varying by at least two orders of magnitude.
Through exposure to the histone deacetylase inhibitor Vorinostat,
our cultures in the RCCS confirm the markedly enhanced
resistance conferred by 3D culture (2.5 fold and 13.5 fold for
U87 and KNS42 cells respectively) which has significant
implications for pre-clinical drug testing strategies and dosage
regimes to be utilized in vivo. A significant over-estimate of agent
potency is likely using solely 2D data. Even when considering
Vorinostat exposure in brain tumor neurosphere cultures (IC50
0.5 mM) that enhance for cancer stem/progenitor cells [83], the
RCCS aggregates are relatively more resistant indicating that the
RCCS may provide a better in vitro system to evaluate agents
targeting stem/progenitor pathways. A key feature of RCCS
culture is the creation of a tissue barrier between agents applied
exogenously and cells deep within the aggregate. This creates the
necessity for agents to penetrate significant depths into tissue,
replicating in vivo conditions. This may be further compounded by
the formation of cell-secreted ECM within aggregates that may
limit drug penetrance and enhance integrin-mediated pro-survival
signaling [73,84]. Such considerations are of key importance when
considering the interaction between drugs and also the genetic and
epigenetic profiles emerging from various methods of culture. The
more resistant phenotype of RCCS aggregates may be directly
associated with a lack of homogenous drug exposure within the
culture. However, our results do not exclude the possibility that
the RCCS microenvironment facilitates the creation of a niche
that enriches for and/or harbors brain tumor sub-populations that
are intrinsically resistant to Vorinostat. It is likely that both
phenomena contribute to the relatively more resistant phenotype
in 3D compared to 2D cultures. The increased resistance shown
by aggregates containing areas of hypoxic cells may be consistent
with enrichment of glioma stem-like cells in hypoxic and vascular
niches that may be intrinsically resistant to chemotherapy
[15,57,63].
Importantly, our findings contrast to a recent study assessing the
efficacy of Vorinostat against ependymoma brain tumor stem cells
propagated using the neurosphere assay. Witt and colleagues
report an IC50 value of 0.78 mM when ependymoma neurosphere
cultures were treated to a clinically achievable concentration range
of Vorinostat and abolition of neurosphere initiating capacity (i.e.
self-renewal capacity) at an IC50 of 0.5 mM [83]. Based solely on
IC50 values, the ependymoma neurosphere cultures were 16–17
fold more sensitive than our RCCS aggregate cultures, supporting
the notion that the RCCS tumor microenvironment induces
greater intrinsic tumor cell resistance and/or better reflects
difficulties in achieving effective drug dose penetration in vivo.
However, we cannot exclude the possibility that differences in
Vorinostat efficacy is at least in part due to the different cell types
and lines used in each study. In a similar finding, treatment of
GBM neurospheres with the telomerase antagonist Imetelstat, led
to an IC50 value of 2 mM after prolonged 4-week exposure [85]
enforcing the hypothesis that neurospheres are relatively more
sensitive than RCCS aggregates. IC50 values detected in the
micromolar range in our study highlight a caveat of standard 2D
drug screens where an agent is typically discarded if its potency is
not in the nanomolar range. Conversely there are instances of
clinically failed anti-cancer compounds with nanomolar potency
in vitro [86]. We propose introducing the RCCS as a second tier
preclinical efficacy/toxicity testing tool, whereby targets forwarded
from 2D drug screens will be further scrutinized in the RCCS
prior to the uptake of lead compounds for in vivo trials.
Furthermore it will also be important to consider sequential
exposure of RCCS aggregates to drug combinations as enhanced
Figure 8. Fresh tissue explant culture in the RCCS maintains primary tumor phenotypes. A – C Three week primary explant cultures of
pediatric anaplastic ependymoma stained immunohistochemically for CD105, CD31 and Ki67 respectively, demonstrating rim/core division with
sparsely cellular core and positivity for vessel markers and Ki67. D – F Immunohistochemistry against CD105, CD31 and Ki67 respectively on primary
tumor sections from the same pediatric anaplastic ependymoma from which the explant was derived in A–C for comparison. Scale bars 25 mm in C,
100 mm in all others.
doi:10.1371/journal.pone.0052335.g008
Dynamic 3D Brain Tumor Culture
PLOS ONE | www.plosone.org 15 December 2012 | Volume 7 | Issue 12 | e52335
doxorubicin accumulation and toxicity has recently been shown
when tumor spheroids were pre-treated with mitoxantrone or
paclitaxel [87].
We have also demonstrated that the RCCS can be used as
a system for maintaining viable explants of primary tumor direct
from surgery for at least 3 weeks, a distinct advantage over
alternative 3D spheroid culture systems [24,28,29,30]. Viable
dividing cells are maintained and internal architecture is preserved
including the presence of endothelial cells. The centre of explants
develops necrotic areas in a similar fashion to cultured aggregates,
indicating a similar tolerance level to hypoxia. Further investiga-
tions will encompass more clinically-relevant drug testing against
these primary explants which may allow prediction of the response
of the tumor in the patient to the same agent. Array real-time-
PCR shows clear differences in gene expression between early
passage cell lines derived from the tumor and subsequently
cultured in 2D and tumor explants cultured in the RCCS.
Conclusions
Our comprehensive characterization demonstrates that 3D
RCCS culture of high grade brain tumor cells has profound effects
on the genetic, epigenetic and metabolic profiles of cultured cells,
with these cells residing as an intermediate phenotype between
that of 2D cultures and primary tumors. We have additionally
shown that RCCS GBM aggregates are relatively more resistant to
the HDACi Vorinostat when compared to 2D monolayer cultures
and likely represents a more faithful drug response observed in the
clinical setting. The RCCS provides a platform for undertaking
a variety of investigations in the Cancer and Neuroscience fields
and our findings encourage broad utility of this in vitro experi-
mental system to interrogate normal and dysregulated neural cell
behavior and to evaluate candidate therapeutic compounds. We
would anticipate that RCCS cultures of other cell types and
primary tissue would behave very differently compared to 2D
culture methods and the RCCS could have wider applicability to
testing therapies against other neuronal and glial cell systems as
well as wider applicability in the cancer field. Treatment advances
for brain tumors and other neurological disorders will be based on
a thorough understanding of the molecular pathways involved
with the pathologies in question. It seems imperative that we
should model diseases and test therapies using in vitro systems that
approximate the in vivo situation as closely as possible to give the
best chances of therapies successful in vitro maintaining their
effectiveness in animal or clinical trials. The RCCS offers a means
of achieving key facets of gene expression and metabolism using an
in vitro model and presents an opportunity to advance our
understanding of how the heterogeneity and differing environ-
mental pressures within a tumor contribute to its overall biology
and response to therapeutic agents.
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(TIF)
Table S1 ECM genes PCR array.
(XLS)
Table S2 PCR primer data.
(XLS)
Table S3 Nanostring probes and targets.
(XLS)
Table S4 Full list genes differentially expressed ECM
arrays.
(XLS)
Table S5 Full list genes differentially expressed U87 3d
vs. 2d.
(XLS)
Table S6 Full list genes differentially expressed KNS42
3d vs. 2d.
(XLS)
Table S7 Full list genes differentially expressed U87
tumor vs. 2d vs. 3d.
(XLS)
Acknowledgments
The authors thank Dr, Chris Jones and Dr. Naveed Khan for kindly
providing the KNS42 and HBMEC cell lines respectively. We would also
like to thank the Nottingham Histopathology Department (particularly J.
Lowe and K. Robson) for assistance and the Biological Studies Committee
of the UK Children’s Cancer and Leukemia Group.
Author Contributions
Conceived and designed the experiments: SJS RR. Performed the
experiments: SJS JHW CVR RRP. Analyzed the data: SJS RR MW.
Contributed reagents/materials/analysis tools: ACP FRAJR. Wrote the
paper: SJS RR MW RGG. Critically analysed the manuscript: SJS RR
DCM RGG.
References
1. Harma V, Virtanen J, Makela R, Happonen A, Mpindi J-P, et al. (2010) A
Comprehensive Panel of Three-Dimensional Models for Studies of Prostate
Cancer Growth, Invasion and Drug Responses. Plos One 5: e10431.
2. Burdett E, Kasper FK, Mikos AG, Ludwig JA (2010) Engineering Tumors: A
Tissue Engineering Perspective in Cancer Biology. Tissue Engineering Part B-
Reviews 16: 351–359.
3. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates?
Nature Reviews Drug Discovery 3: 711–715.
4. Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, et al. (2010) Integrated
molecular genetic profiling of pediatric high-grade gliomas reveals key
differences with the adult disease. J Clin Oncol 28: 3061–3068.
5. Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, et al.
(2011) An Integrated In Vitro and In Vivo High-Throughput Screen Identifies
Treatment Leads for Ependymoma. Cancer Cell 20: 384–399.
6. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, et al. (2011) Mosaic
amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer
Cell 20: 810–817.
7. Birgersdotter A, Sandberg R, Ernberg I (2005) Gene expression perturbation
in vitro - A growing case for three-dimensional (3D) culture systems. Seminars in
Cancer Biology 15: 405–412.
8. Elliott NT, Yuan F (2011) A Review of Three-Dimensional In Vitro Tissue
Models for Drug Discovery and Transport Studies. Journal of Pharmaceutical
Sciences 100: 59–74.
9. Weinstein JN (2002) ’Omic’ and hypothesis-driven research in the molecular
pharmacology of cancer. Current Opinion in Pharmacology 2: 361–365.
10. Sos ML, Michel K, Zander T, Weiss J, Frommolt P, et al. (2009) Predicting drug
susceptibility of non-small cell lung cancers based on genetic lesions. Journal of
Clinical Investigation 119: 1727–1740.
11. Hutmacher DW, Horch RE, Loessner D, Rizzi S, Sieh S, et al. (2009)
Translating tissue engineering technology platforms into cancer research.
Journal of Cellular and Molecular Medicine 13: 1417–1427.
12. dit Faute MA, Laurent L, Ploton D, Poupon MF, Jardillier JC, et al. (2002)
Distinctive alterations of invasiveness, drug resistance and cell-cell organization
in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug
resistant variant. Clin Exp Metastasis 19: 161–168.
13. Fischbach C, Chen R, Matsumoto T, Schmelzle T, Brugge JS, et al. (2007)
Engineering tumors with 3D scaffolds. Nat Methods 4: 855–860.
14. Yuhas JM, Li AP, Martinez AO, Ladman AJ (1977) Simplified method for
production and growth of multicellular tumor spheroids. Cancer Research 37:
3639–3643.
Dynamic 3D Brain Tumor Culture
PLOS ONE | www.plosone.org 16 December 2012 | Volume 7 | Issue 12 | e52335
15. Acker H, Carlsson J, Muellerklieser W, Sutherland RM (1987) Comparative
pO2 measurements in cell spheroids cultured with different techniques. British
Journal of Cancer 56: 325–327.
16. Bates RC, Edwards NS, Yates JD (2000) Spheroids and cell survival. Critical
Reviews in Oncology Hematology 36: 61–74.
17. Buffa FM, West C, Byrne K, Moore JV, Nahum AE (2001) Radiation response
and cure rate of human colon adenocarcinoma spheroids of different size: The
significance of hypoxia on tumor control modelling. International Journal of
Radiation Oncology Biology Physics 49: 1109–1118.
18. Frankel A, Buckman R, Kerbel RS (1997) Abrogation of taxol-induced G(2)-M
arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor
spheroids. Cancer Research 57: 2388–2393.
19. Nicholson KM, Bibby MC, Phillips RM (1997) Influence of drug exposure
parameters on the activity of paclitaxel in multicellular spheroids. European
Journal of Cancer 33: 1291–1298.
20. Pampaloni F, Reynaud EG, Stelzer EHK (2007) The third dimension bridges
the gap between cell culture and live tissue. Nature Reviews Molecular Cell
Biology 8: 839–845.
21. Biggs T, Foreman J, Sundstrom L, Regenass U, Lehembre F (2011) Antitumor
Compound Testing in Glioblastoma Organotypic Brain Cultures. Journal of
Biomolecular Screening 16: 805–817.
22. Stewart DJ, Richard MT, Benoit B, Hugenholtz H, Russell N, et al. (1984)
Cisplatin plus cytosine-arabinoside in adults with malignant gliomas. Journal of
Neuro-Oncology 2: 29–34.
23. Swinnen LJ, Rankin C, Carraway H, Albain KS, Townsend JJ, et al. (2008) A
phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent
hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant
gliomas (Southwest Oncology Group S9149). Journal of Neuro-Oncology 86:
353–358.
24. Vinci M, Gowan S, Boxall F, Patterson L, Zimmermann M, et al. (2012)
Advances in establishment and analysis of three-dimensional tumor spheroid-
based functional assays for target validation and drug evaluation. Bmc Biology
10: 29.
25. De Witt Hamer PC, Van Tilborg AAG, Eijk PP, Sminia P, Troost D, et al.
(2008) The genomic profile of human malignant glioma is altered early in
primary cell culture and preserved in spheroids. Oncogene 27: 2091–2096.
26. Ernst A, Hofmann S, Ahmadi R, Becker N, Korshunov A, et al. (2009) Genomic
and Expression Profiling of Glioblastoma Stem Cell-Like Spheroid Cultures
Identifies Novel Tumor-Relevant Genes Associated with Survival. Clinical
Cancer Research 15: 6541–6550.
27. Grant DS, Kinsella JL, Fridman R, Auerbach R, Piasecki BA, et al. (1992)
Interaction of endothelial-cells with a laminin-A chaine peptide (SIKVAV)
in vitro and induction of angiogenic behavior in vivo. Journal of Cellular
Physiology 153: 614–625.
28. Li Q, Chen C, Kapadia A, Zhou Q, Harper MK, et al. (2011) 3D Models of
Epithelial-Mesenchymal Transition in Breast Cancer Metastasis: High-
Throughput Screening Assay Development, Validation, and Pilot Screen.
Journal of Biomolecular Screening 16: 141–154.
29. Campbell JJ, Davidenko N, Caffarel MM, Cameron RE, Watson CJ (2011) A
Multifunctional 3D Co-Culture System for Studies of Mammary Tissue
Morphogenesis and Stem Cell Biology. Plos One 6: e25661.
30. Ingthorsson S, Sigurdsson V, Fridriksdottir A, Jr., Jonasson JG, Kjartansson J, et
al. (2010) Endothelial cells stimulate growth of normal and cancerous breast
epithelial cells in 3D culture. BMC research notes 3: 184–184.
31. Hammond TG, Hammond JM (2001) Optimized suspension culture: the
rotating-wall vessel. American Journal of Physiology-Renal Physiology 281:
F12–F25.
32. Schwarz RP, Goodwin TJ, Wolf DA (1992) Cell culture for three-dimensional
modeling in rotating-wall vessels: an application of simulated microgravity.
J Tissue Cult Methods 14: 51–57.
33. Skardal A, Sarker SF, Crabbe A, Nickerson CA, Prestwich GD (2010) The
generation of 3-D tissue models based on hyaluronan hydrogel-coated
microcarriers within a rotating wall vessel bioreactor. Biomaterials 31: 8426–
8435.
34. Pellegrini M, Di Siena S, Claps G, Di Cesare S, Dolci S, et al. (2010)
Microgravity promotes differentiation and meiotic entry of postnatal mouse male
germ cells. PLoS One 5: e9064.
35. Barrila J, Radtke AL, Crabbe A, Sarker SF, Herbst-Kralovetz MM, et al. (2010)
Organotypic 3D cell culture models: using the rotating wall vessel to study host-
pathogen interactions. Nat Rev Microbiol 8: 791–801.
36. Sung SY, Hsieh CL, Law A, Zhau HE, Pathak S, et al. (2008) Coevolution of
prostate cancer and bone stroma in three-dimensional coculture: implications for
cancer growth and metastasis. Cancer Res 68: 9996–10003.
37. Laguinge LM, Lin S, Samara RN, Salesiotis AN, Jessup JM (2004) Nitrosative
stress in rotated three-dimensional colorectal carcinoma cell cultures induces
microtubule depolymerization and apoptosis. Cancer Res 64: 2643–2648.
38. Gaspar N, Marshall L, Perryman L, Bax DA, Little SE, et al. (2010) MGMT-
Independent Temozolomide Resistance in Pediatric Glioblastoma Cells
Associated with a PI3-Kinase-Mediated HOX/Stem Cell Gene Signature.
Cancer Research 70: 9243–9252.
39. Bielen A, Perryman L, Box GM, Valenti M, Brandon AdH, et al. (2011)
Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by
Combinatorial Targeting of PDGFR alpha/beta. Molecular Cancer Therapeu-
tics 10: 1407–1418.
40. Phillips WT, Goins B, Bao A, Vargas D, Guttierez JE, et al. (2012) Rhenium-186
liposomes as convection-enhanced nanoparticle brachytherapy for treatment of
glioblastoma. Neuro-Oncology 14: 416–425.
41. Schnell O, Romagna A, Jaehnert I, Albrecht V, Eigenbrod S, et al. (2012)
Kruppel-Like Factor 8 (KLF8) Is Expressed in Gliomas of Different WHO
Grades and Is Essential for Tumor Cell Proliferation. Plos One 7: e30429.
42. Rahman R, Osteso-Ibanez T, Hirst RA, Levesley J, Kilday J-P, et al. (2010)
Histone Deacetylase Inhibition Attenuates Cell Growth with Associated
Telomerase Inhibition in High-Grade Childhood Brain Tumor Cells. Molecular
Cancer Therapeutics 9: 2568–2581.
43. de Antonellis P, Medaglia C, Cusanelli E, Andolfo I, Liguori L, et al. (2011)
MiR-34a Targeting of Notch Ligand Delta-Like 1 Impairs CD15(+)/CD133(+)
Tumor-Propagating Cells and Supports Neural Differentiation in Medulloblas-
toma. Plos One 6: e24584.
44. Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, et al. (2012) Polo-Like
Kinase 1 Inhibition Kills Glioblastoma Multiforme Brain Tumor Cells in Part
Through Loss of SOX2 and Delays Tumor Progression in Mice. Stem Cells 30:
1064–1075.
45. Fotovati A, Abu-Ali S, Wang P-S, Deleyrolle LP, Lee C, et al. (2011) YB-1
Bridges Neural Stem Cells and Brain Tumor-Initiating Cells via Its Roles in
Differentiation and Cell Growth. Cancer Research 71: 5569–5578.
46. Silvestrini F, Tiburcio M, Bertuccini L, Alano P (2012) Differential Adhesive
Properties of Sequestered Asexual and Sexual Stages of Plasmodium falciparum
on Human Endothelial Cells Are Tissue Independent. Plos One 7: e31567.
47. Schwerk C, Papandreou T, Schuhmann D, Nickol L, Borkowski J, et al. (2012)
Polar Invasion and Translocation of Neisseria meningitidis and Streptococcus
suis in a Novel Human Model of the Blood-Cerebrospinal Fluid Barrier. Plos
One 7: e30069.
48. Wilson M, Reynolds G, Kauppinen RA, Arvanitis TN, Peet AC (2010) A
constrained least-squares approach to the automated quantitation of in vivo (1)H
magnetic resonance spectroscopy data. Magn Reson Med 65: 1–12.
49. Smith SJ, Tilly H, Ward JH, Macarthur DC, Lowe J, et al. (2012) CD105
(Endoglin) exerts prognostic effects via its role in the microvascular niche of
paediatric high grade glioma. Acta Neuropathol 124: 99–110.
50. Richon VM, O’Brien JP (2002) Histone deacetylase inhibitors: a new class of
potential therapeutic agents for cancer treatment. Clin Cancer Res 8: 662–664.
51. Buchwald M, Kramer OH, Heinzel T (2009) HDACi–targets beyond
chromatin. Cancer Lett 280: 160–167.
52. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, et al. (2009) Phase II
trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer
treatment group study. J Clin Oncol 27: 2052–2058.
53. Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, et al. (2010)
Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children’s
Oncology Group phase I consortium report. J Clin Oncol 28: 3623–3629.
54. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H (2012) The
brain tumor microenvironment. Glia 60: 502–514.
55. Lathia JD, Heddleston JM, Venere M, Rich JN (2011) Deadly teamwork: neural
cancer stem cells and the tumor microenvironment. Cell Stem Cell 8: 482–485.
56. Galan-Moya EM, Le Guelte A, Lima Fernandes E, Thirant C, Dwyer J, et al.
(2011) Secreted factors from brain endothelial cells maintain glioblastoma stem-
like cell expansion through the mTOR pathway. EMBO Rep 12: 470–476.
57. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, et al. (2007) A
perivascular niche for brain tumor stem cells. Cancer Cell 11: 69–82.
58. Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, et al. (2004) Hypoxia
is important in the biology and aggression of human glial brain tumors. Clin
Cancer Res 10: 8177–8184.
59. Olin MR, Andersen BM, Litterman AJ, Grogan PT, Sarver AL, et al. (2011)
Oxygen is a master regulator of the immunogenicity of primary human glioma
cells. Cancer Res 71: 6583–6589.
60. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schaenzer A, et al. (2010) A
hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor
2 alpha. Brain 133: 983–995.
61. Svensson KJ, Kucharzewska P, Christianson HC, Skold S, Lofstedt T, et al.
(2011) Hypoxia triggers a proangiogenic pathway involving cancer cell
microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothe-
lial cells. Proc Natl Acad Sci U S A 108: 13147–13152.
62. Cooper LA, Gutman DA, Chisolm C, Appin C, Kong J, et al. (2012) The
Tumor Microenvironment Strongly Impacts Master Transcriptional Regulators
and Gene Expression Class of Glioblastoma. Am J Pathol 180: 2108–2119.
63. Bar EE, Lin A, Mahairaki V, Matsui W, Eberhart CG (2010) Hypoxia Increases
the Expression of Stem-Cell Markers and Promotes Clonogenicity in
Glioblastoma Neurospheres. American Journal of Pathology 177: 1491–1502.
64. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN (2009) The
hypoxic microenvironment maintains glioblastoma stem cells and promotes
reprogramming towards a cancer stem cell phenotype. Cell Cycle 8: 3274–3284.
65. Li Z, Bao S, Wu Q, Wang H, Eyler C, et al. (2009) Hypoxia-Inducible Factors
Regulate Tumorigenic Capacity of Glioma Stem Cells. Cancer Cell 15: 501–
513.
66. Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, et al. (2007) Cellular
adaptations to hypoxia and acidosis during somatic evolution of breast cancer.
Br J Cancer 97: 646–653.
67. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004)
Identification of human brain tumour initiating cells. Nature 432: 396–401.
Dynamic 3D Brain Tumor Culture
PLOS ONE | www.plosone.org 17 December 2012 | Volume 7 | Issue 12 | e52335
68. Tung YC, Hsiao AY, Allen SG, Torisawa YS, Ho M, et al. (2011) High-
throughput 3D spheroid culture and drug testing using a 384 hanging drop
array. Analyst 136: 473–478.
69. Hassan SB, de la Torre M, Nygren P, Karlsson MO, Larsson R, et al. (2001) A
hollow fiber model for in vitro studies of cytotoxic compounds: activity of the
cyanoguanidine CHS 828. Anticancer Drugs 12: 33–42.
70. Hicks KO, Pruijn FB, Baguley BC, Wilson WR (2001) Extravascular transport
of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)ethy-
l]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular
layers of tumor cells. J Pharmacol Exp Ther 297: 1088–1098.
71. Nyga A, Cheema U, Loizidou M (2011) 3D tumour models: novel in vitro
approaches to cancer studies. J Cell Commun Signal 5: 239–248.
72. Kim C, Bang JH, Kim YE, Lee SH, Kang JY (2012) On-chip anticancer drug
test of regular tumor spheroids formed in microwells by a distributive
microchannel network. Lab on a chip 12: 4135–4142.
73. Loessner D, Stok KS, Lutolf MP, Hutmacher DW, Clements JA, et al. (2010)
Bioengineered 3D platform to explore cell-ECM interactions and drug resistance
of epithelial ovarian cancer cells. Biomaterials 31: 8494–8506.
74. Oshiro S, Tsugu H, Komatsu F, Abe H, Onishi H, et al. (2007) Quantitative
assessment of gliomas by proton magnetic resonance spectroscopy. Anticancer
Res 27: 3757–3763.
75. Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, et al.
(2012) Reduced phosphocholine and hyperpolarized lactate provide magnetic
resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro
Oncol 14: 315–325.
76. Smith BH, Gazda LS, Conn BL, Jain K, Asina S, et al. (2011) Three-
dimensional culture of mouse renal carcinoma cells in agarose macrobeads
selects for a subpopulation of cells with cancer stem cell or cancer progenitor
properties. Cancer Res 71: 716–724.
77. Davies NP, Wilson M, Natarajan K, Sun Y, MacPherson L, et al. (2010) Non-
invasive detection of glycine as a biomarker of malignancy in childhood brain
tumours using in-vivo 1H MRS at 1.5 tesla confirmed by ex-vivo high-resolution
magic-angle spinning NMR. NMR Biomed 23: 80–87.
78. Bibby MC (2004) Orthotopic models of cancer for preclinical drug evaluation:
advantages and disadvantages. European Journal of Cancer 40: 852–857.
79. Fiebig HH, Maier A, Burger AM (2004) Clonogenic assay with established
human tumour xenografts: correlation of in vitro to in vivo activity as a basis for
anticancer drug discovery. European Journal of Cancer 40: 802–820.
80. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti J, et al. (2001)
Relationships between drug activity in NCI preclinical in vitro and in vivo
models and early clinical trials. British Journal of Cancer 84: 1424–1431.
81. Lamfers ML, Hemminki A (2004) Multicellular tumor spheroids in gene therapy
and oncolytic virus therapy. Current Opinion in Molecular Therapeutics 6:
403–411.
82. Suggitt M, Bibby MC (2005) 50 years of preclinical anticancer drug screening:
Empirical to target-driven approaches. Clinical Cancer Research 11: 971–981.
83. Milde T, Kleber S, Korshunov A, Witt H, Hielscher T, et al. (2011) A novel
human high-risk ependymoma stem cell model reveals the differentiation-
inducing potential of the histone deacetylase inhibitor Vorinostat. Acta
Neuropathol 122: 637–650.
84. Sodek KL, Ringuette MJ, Brown TJ (2009) Compact spheroid formation by
ovarian cancer cells is associated with contractile behavior and an invasive
phenotype. International Journal of Cancer 124: 2060–2070.
85. Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, et al. (2010) The
telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating
cells leading to decreased proliferation and tumor growth. Clin Cancer Res 16:
154–163.
86. Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, et al. (2005) Valdecoxib:
assessment of cyclooxygenase-2 potency and selectivity. J Pharmacol Exp Ther
312: 1206–1212.
87. Perche F, Torchilin VP (2012) Cancer cell spheroids as a model to evaluate
chemotherapy protocols. Cancer Biology & Therapy 13: 1205–1213.
Dynamic 3D Brain Tumor Culture
PLOS ONE | www.plosone.org 18 December 2012 | Volume 7 | Issue 12 | e52335
